40527-52-4

Usage

Uses

Used in Skincare and Cosmetics:
Ferulic acid is used as an additive in skincare and cosmetic products for its ability to protect against UV radiation and environmental damage. Its antioxidant properties help to maintain the health and appearance of the skin, making it a valuable component in anti-aging and skin-protective formulations.
Used in Food Preservation:
In the food industry, ferulic acid is utilized as a natural additive to extend the shelf life of products and maintain their freshness. Its antioxidant characteristics help to prevent the oxidation of fats and oils, which can lead to rancidity and spoilage.
Used in Pharmaceutical Research:
Ferulic acid is being researched for its potential use in the development of pharmaceuticals. Its anti-inflammatory and anti-cancer properties make it a promising candidate for the treatment of various chronic diseases and conditions.
Used in Drug Development:
The potential of ferulic acid in drug development is being explored due to its antioxidant and other beneficial properties. It may contribute to the creation of novel therapeutic agents for a range of health issues, including cancer and inflammation-related disorders.

InChI:InChI=1/C11H12O3/c1-8(11(12)13)7-9-3-5-10(14-2)6-4-9/h3-7H,1-2H3,(H,12,13)/b8-7+

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 79-41-4 poly(methacrylic acid) 
• 69390-19-8 4-(4'-methoxyphenyl)-3-methyl-3-buten-2-one 
• 123-11-5 4-methoxy-benzaldehyde 
• 123-62-6 propionic acid anhydride 
• 104-94-9 4-methoxy-aniline 
• 516-05-2 methyl-propanedioic acid 
• 591-31-1 3-methoxy-benzaldehyde 
• 30094-28-1 2-(diethylphosphono)propionic acid 
• 696-62-8 para-iodoanisole 
• 126356-04-5 (E)-methyl 2-methyl-3-(p-methoxyphenyl)prop-2-enoate 
• 144-55-8 sodium hydrogencarbonate 
• 1039703-89-3 ethyl (2Z)-3-(4-methoxyphenyl)-2-[(trimethylsilyl)methyl]prop-2-enoate 
• 1367876-22-9 [(Z)-2-methoxycarbonyl-3-(4-methoxyphenyl)-2-propenyl]triphenylphosphonium bromide 

Downstream Products

• 124-38-9 carbon dioxide 
• 104-46-1 anethole 
• 56189-94-7 methyl (2E,4E)-5-(4-methoxyphenyl)-4-methylpenta-2,4-dienoate 
• 126356-04-5 (E)-methyl 2-methyl-3-(p-methoxyphenyl)prop-2-enoate 
• 52427-11-9 3-(4-methoxyphenyl)-2-methylpropionic acid 
• 61227-51-8 3-(3-methoxyphenyl)-2-methylpropionic acid 
• 353476-46-7 (E)-N-methoxy-N-methyl-3-(4-methoxyphenyl)-2-methyl-acrylamide 
• 122-84-9 4-methoxybenzyl methyl ketone 
• 1228457-91-7 ethyl (1S,5S)-1-ethyl-3-hydroxy-5-(4-methoxyphenyl)-4-methyl-2-oxocyclopent-3-enecarboxylate 
• 1228457-77-9 ethyl (E)-2-ethyl-6-(4-methoxyphenyl)-5-methyl-3,4-dioxohex-5-enoate 

Relevant academic research and scientific papers

The synergistic copper/ppm Pd-catalyzed hydrocarboxylation of alkynes with formic acid as a CO surrogate as well as a hydrogen source: An alternative indirect utilization of CO2

An unprecedented strategy has been developed involving the earth-abundant Cu-catalyzed hydrocarboxylation of alkynes with HCOOH to (E)-acrylic derivatives with high regio- and stereoselectivity via synergistic effects with ppm levels of a Pd catalyst. Both symmetrical and unsymmetrical alkynes bearing various functional groups were successfully hydrocarboxylated with HCOOH, and the modification of a pharmaceutical molecule exemplified the practicability of this process. This protocol employs HCOOH as both a CO surrogate and hydrogen donor with 100% atom economy and it can be viewed as an alternative approach for indirect CO2 utilization. Mechanistic investigations indicate a Cu/ppm Pd cooperative catalysis mechanism via alkenylcopper species as potential intermediates formed from Cu-hydride active catalytic species with HCOOH as a hydrogen source. This bimetallic system involving inexpensive Cu and trace Pd provides a reliable and efficient hydrocarboxylation method to access industrially useful acrylic derivatives with HCOOH as a hydrogen source, and it provides novel clues for optimizing other Cu-H-related co-catalytic systems.

Copper-Photocatalyzed Contra-Thermodynamic Isomerization of Polarized Alkenes

The contra-thermodynamic isomerization of α- and β-substituted cinnamate derivatives catalyzed by the Cu(OAc)2/rac-BINAP complex under blue light irradiation is reported. The use of an oxazolidinone template, which favored the complexation of the copper catalyst to the substrate, allowed the E → Z isomerization of the catalytically formed chromophore under simple and robust reaction conditions in good to excellent ratios. The mechanism of this process based on the transient formation of a chromophore was also studied.

Macrolide Synthesis through Intramolecular Oxidative Cross-Coupling of Alkenes

A RhIII-catalyzed intramolecular oxidative cross-coupling between double bonds for the synthesis of macrolides is described. Under the optimized reaction conditions, macrocycles containing a diene moiety can be formed in reasonable yields and with excellent chemo- and stereoselectivity. This method provides an efficient approach to synthesize macrocyclic compounds containing a 1,3-conjugated diene structure.

Enantioselective Cobalt-Catalyzed Sequential Nazarov Cyclization/Electrophilic Fluorination: Access to Chiral α-Fluorocyclopentenones

A newly designed thiazoline iminopyridine ligand for enantioselective cobalt-catalyzed sequential Nazarov cyclization/electrophilic fluorination was developed. Various chiral α-fluorocyclopentenones were prepared with good yields and diastereo- and enantioselectivities. Further derivatizations could be easily carried out to provide chiral cyclopentenols with three contiguous stereocenters. Furthermore, a direct deesterification of fluorinated products could afford chiral α-single fluorine-substituted cyclopentenones.

COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER

Disclosed are compounds of formulas I and II, in which R, R0, R1-R4, R7-R10, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds. The compounds and pharmaceutical compositions are for use in treating or preventing diseases, for example, cancer.

INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF

Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES

Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

A practical, enantioselective synthesis of the fragrances canthoxal and silvial, and evaluation of their olfactory activity

The fragrances (S)-(+)- and (R)-(-)-canthoxal [(S)-(+)- and (R)-(-)-3-(4-methoxyphenyl)-2-methylpropanal] and (+)- and (-)-Silvial [(+)- and (-)-3-(4-isobutylphenyl)-2-methylpropanal] have been synthesized in high enantiopurity via a simple fou

Synthesis of chiral α-benzyl-β2-hydroxy carboxylic acids through iridium-catalyzed asymmetric hydrogenation of α- oxymethylcinnamic acids

An asymmetric hydrogenation of α-oxymethylcinnamic acids was developed by using chiral spiro phosphine-oxazoline/iridium complexes as catalysts to prepare β2-hydroxycarboxylic acids with high reactivity (TON up to 2000) and excellent enantioselectivity (up to 99.5% ee). By using this highly efficient asymmetric hydrogenation as a key step, a concise total synthesis of natural product homoisoflavone (S)-(+)-4 was accomplished. An asymmetric hydrogenation of α-oxymethylcinnamic acids was developed to prepare β2-hydroxycarboxylic acids with high reactivity (TON up to 2000) and excellent enantioselectivity (up to 99.5% ee), which was applied to a concise total synthesis of a natural product homoisoflavone. Copyright

Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

RXRα represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXRα and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXRα (tRXRα) with the p85α regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXRα-dependent AKT activation. A new compound 30 was identified to have improved biological activity.